Selective decontamination of the digestive tract with norfloxacin in the prevention of ICU-acquired infections: a prospective randomized study

Intensive Care Med. 1989;15(7):424-31. doi: 10.1007/BF00255597.

Abstract

The efficacy of a relatively cheap regimen of selective decontamination (SDD) was evaluated in a diverse population of ICU patients. Patients requiring prolonged ICU stay (greater than 5 days) were randomly allocated to a treatment group or control group. Control patients (n = 52) received perioperative antimicrobial prophylaxis and antibiotic treatment was instituted only on sound clinical and bacteriological criteria. Treated patients (n = 48) received gastro-intestinal and oro-pharyngeal decontamination with polymyxin E, norfloxacin, amphotericin B and systemic antibiotic prophylaxis with trimethoprim until decontamination was achieved. The rate of gram-positive infections was not altered by SDD. The incidence of gram-negative respiratory tract, urinary tract and line infections was significantly reduced from 44%, 27% and 15% respectively in the control group to 6%, 4% and 0% in the treatment group. Mortality from nosocomial sepsis and overall mortality were also significantly reduced from 15% and 54% to 0% and 31% respectively. The ICU stay was not reduced by SDD, nor was time on the ventilator or use of therapeutic antibiotics. The reduction in morbidity and mortality was achieved at a relatively low cost.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Infections / drug therapy
  • Bacterial Infections / epidemiology
  • Bacterial Infections / prevention & control*
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology
  • Cross Infection / prevention & control*
  • Digestive System*
  • Female
  • Gram-Negative Bacteria
  • Humans
  • Incidence
  • Intensive Care Units*
  • Male
  • Middle Aged
  • Norfloxacin / standards
  • Norfloxacin / therapeutic use*
  • Premedication
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Respiratory System*

Substances

  • Norfloxacin